Since its origin, the mission of ECR Pharmaceuticals has been to manufacture primary care products of unexcelled quality and to assure these are available to patients at an affordable price. This philosophy has been reduced to a simple statement: "Quality Products at a Price the Patient Can Afford”. ECR places this phrase on virtually all literature, correspondence, and other information it produces as a daily reminder to our employees and customers of the company’s continuing commitment to healthcare professionals and patients.

ECR Pharmaceuticals was formed in 1990 by three former AH Robins executives, E. Claiborne Robins, Jr., Davis S. Caskey, and Dr. Robert S. Murphey, to continue their long standing interests in the pharmaceutical industry. The development and marketing of cough/cold and analgesic products allowed the firm to develop its initial core internal staff as well as its sales and marketing infrastructure. As the firm evolved, its focus became the development of once daily dosage forms of widely used products which were previously dosed three or four times daily. These formulations improve patient convenience and much needed therapeutic compliance.

In 2007 the firm received its first NDA for the once daily dosed musculoskeletal relaxant, Amrix® (cyclobenzaprine HCl, extended release). The product's potential in the marketplace exceeded ECR's then capabilities and was divested to Cephalon, Inc. It has become a mainstay in the treatment of low back pain. ECR also developed once daily dosed antihistamine formulations, Lodrane 24 and Lodrane 24D, which its sales force currently markets. Other ECR products are the corticosteroid DexPak TaperPak and the analgesic, Bupap.

In February, 2009 ECR was acquired by Hi-Tech Pharmacal, Amityville, NY, a major supplier of liquid, generic prescription products as well as branded OTC pharmaceuticals. (See Newsline). The combined firms provide enhanced synergy toward the development and marketing of various product opportunities, expands product life cycle potential, and solidifies Hi-Tech's position in both the branded and generic marketplace.

ECR products are distributed nationwide and are promoted to healthcare professionals and pharmacies through the firm's expanding sales force. The company has appropriately positioned itself and its sales organization to market not only those products developed internally but to be responsive to product opportunities which may come available through various other sources. It continues to aggressively pursue product technologies which improve patient convenience and compliance, and which provides enhanced patient therapy. It does so with the mission and vision to provide quality, affordable pharmaceutical products to all patients.